<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309136</url>
  </required_header>
  <id_info>
    <org_study_id>AHNATHY</org_study_id>
    <nct_id>NCT04309136</nct_id>
  </id_info>
  <brief_title>Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer</brief_title>
  <official_title>The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: a Single-arm Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid&#xD;
      cancer in the neoadjuvant setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>at the time point of 18 weeks</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0/1 resection rate</measure>
    <time_frame>at the time of surgery</time_frame>
    <description>R0/1 resection rate if operable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>at the time point of 18 weeks</time_frame>
    <description>DCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>from the first drug administration to within 90 days after surgery</time_frame>
    <description>AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>All patients will receive Anlotinib for at least two cycles of neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>Perform surgery if operable after neoadjuvant therapy</description>
    <arm_group_label>Neoadjuvant Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>core needle biopsy</intervention_name>
    <description>Perform core needle biopsy if inoperable after neoadjuvant therapy</description>
    <arm_group_label>Neoadjuvant Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient volunteered to participate in the study and signed an informed consent&#xD;
             form;&#xD;
&#xD;
          -  Pathologically diagnosed locally advanced thyroid cancer, including papillary thyroid&#xD;
             cancer, medullary cancer, follicular cancer, poorly differentiated cancer, etc.,&#xD;
             require surgical resection with or without distant metastasis;&#xD;
&#xD;
          -  Preoperative assessment of invasion or adhesion of at least one of the following&#xD;
             structures / organs, including: trachea, esophagus, common carotid artery, larynx,&#xD;
             anterior vertebral fascia, brachial plexus, intended for surgical treatment;&#xD;
&#xD;
          -  Have at least one measurable lesion (RECIST 1.1);&#xD;
&#xD;
          -  Age 14-80 years, Eastern Cooperative Oncology Group (ECOG) score 0-1;&#xD;
&#xD;
          -  The main organ functions meet the following criteria within 7 days before treatment:&#xD;
&#xD;
               1. Standard blood test (without blood transfusion within 14 days):Hemoglobin (HB)&#xD;
                  ≥90g / L;Absolute neutrophil value (ANC) ≥ 1.5 × 109 / L;Platelet (PLT) ≥80 × 109&#xD;
                  / L&#xD;
&#xD;
               2. Biochemical inspection must meet the following standards:Total bilirubin (TBIL) ≤&#xD;
                  1.5 times the upper limit of normal value (ULN); Alanine aminotransferase (ALT)&#xD;
                  and aspartate aminotransferase (AST) ≤ 2.5 ULN, if with liver metastases, ALT and&#xD;
                  AST ≤ 5 ULN; Serum creatinine (Cr) ≤ 1.5 ULN or creatinine clearance (CCr) ≥ 60ml&#xD;
                  / min;&#xD;
&#xD;
               3. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥ the&#xD;
                  lower limit of normal value (50%).&#xD;
&#xD;
          -  Women of childbearing age should agree to use contraceptives during the study and&#xD;
             within 6 months after the study; negative serum or urine pregnancy tests within 7 days&#xD;
             before study enrollment; men should agree to use contraception during the study period&#xD;
             and within 6 months after the end of the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously used anlotinib or similar VEGFR-TKI small molecule drugs, such as&#xD;
             vandetanib, cabozantinib, lenvatinib, sunitinib, sorafenib and etc.&#xD;
&#xD;
          -  Received external radiation therapy or iodine-131 therapy within the past 3 months; or&#xD;
             planned systemic anti-tumor therapy during this study;&#xD;
&#xD;
          -  Pathologically confirmed non-thyroid epithelial cell-derived malignant tumors&#xD;
             (including lymphoma, metastatic cancer, sarcoma, etc.);&#xD;
&#xD;
          -  With other uncontrolled / under treatment malignancies;&#xD;
&#xD;
          -  Those who have multiple factors (such as inability to swallow) that affect oral&#xD;
             medication;&#xD;
&#xD;
          -  With pleural effusion or ascites, causing respiratory syndrome (≥CTC AE level 2&#xD;
             dyspnea [level 2 dyspnea refers to shortness of breath when a small amount of&#xD;
             activity; affecting instrumental daily activities]);&#xD;
&#xD;
          -  Patients with any severe and / or uncontrolled illness, including:&#xD;
&#xD;
               1. Patients whose blood pressure is still unsatisfactory with a blood pressure&#xD;
                  medication (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥100&#xD;
                  mmHg);&#xD;
&#xD;
               2. Patients with myocardial ischemia or myocardial infarction of grade I or higher&#xD;
                  and congestive heart failure of grade 2 or higher (New York Heart Association&#xD;
                  (NYHA) classification);&#xD;
&#xD;
               3. Sinus bradycardia; or atrioventricular block of more than two degrees, or sinus&#xD;
                  arrest (except for pacemakers); arrhythmia (including QTC ≥480ms); need to be&#xD;
                  used together to extend QTc interval drugs, including those for antiarrhythmic&#xD;
                  treatment;&#xD;
&#xD;
               4. Active or uncontrolled severe infection (≥CTC AE level 2 infection);&#xD;
&#xD;
               5. Patients with cirrhosis, decompensated liver disease, active hepatitis or chronic&#xD;
                  hepatitis;&#xD;
&#xD;
               6. Renal failure requires hemodialysis or peritoneal dialysis;&#xD;
&#xD;
               7. Have a history of immunodeficiency, including those who are HIV positive or have&#xD;
                  other acquired or congenital immunodeficiency diseases, or have a history of&#xD;
                  organ transplantation;&#xD;
&#xD;
               8. Poor blood glucose control in diabetic patients (fasting blood glucose (FBG)&gt;&#xD;
                  10mmol / L);&#xD;
&#xD;
               9. Urine routine indicates urinary protein ≥ ++, and the 24-hour urine protein&#xD;
                  quantification is greater than 1.0 g.&#xD;
&#xD;
          -  received major surgical treatment, incisional biopsy or obvious traumatic injury&#xD;
             within 28 days before enrollment;&#xD;
&#xD;
          -  Patients whose imaging showed that the tumor had invaded the important blood vessels&#xD;
             or the researchers judged that the tumor was likely to invade important blood vessels&#xD;
             during the subsequent study period and caused fatal bleeding;&#xD;
&#xD;
          -  Patients with any signs or history of bleeding regardless of severity; patients with&#xD;
             any bleeding or bleeding event ≥ CTCAE level 3 within 4 weeks prior to grouping with&#xD;
             unhealed wounds, ulcers or fractures&#xD;
&#xD;
          -  Arterial / venous thrombosis events, such as cerebrovascular accidents (including&#xD;
             transient ischemic attacks), deep vein thrombosis and pulmonary embolism within 6&#xD;
             months;&#xD;
&#xD;
          -  History of aneurysm;&#xD;
&#xD;
          -  Those with a history of epilepsy or neurological disorders with ataxia in need of&#xD;
             treatment;&#xD;
&#xD;
          -  People with a history of psychotropic substance abuse who are unable to quit or have&#xD;
             mental disorders;&#xD;
&#xD;
          -  Those with a history of peripheral nervous system disease and muscle strength below 3;&#xD;
&#xD;
          -  Those who have participated in other clinical trials of anti-tumor drugs within four&#xD;
             weeks or are conducting other clinical trials;&#xD;
&#xD;
          -  According to the investigator's judgment, there are concomitant diseases that&#xD;
             seriously endanger the safety of patients or affect patients to complete the research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thyroid cancer</keyword>
  <keyword>locally advanced</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>Anlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

